Abiopharma

🔍 Kandal Philipp Wolfgang Josef (Executive)

Company: Grab Holdings Ltd (GRAB)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 569,064 shares of Class A Ordinary Shares (Direct)
  Date: 2026-04-15 | Code: C | equity_swap_involved: 0 | shares_owned_after: 2,285,791.00 | transaction_form_type: 4
• Acquired 411,906 shares of Class A Ordinary Shares (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,697,697.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 471,483 shares of Class A Ordinary Shares (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,169,180.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,006,250 shares of Class A Ordinary Shares (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,175,430.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 30,000 shares of Class A Ordinary Shares at $3.9162 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,145,430.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 20,000 shares of Class A Ordinary Shares at $4.0 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,125,430.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 569,064 shares of Class B Ordinary Shares (Derivative)
  Date: 2026-04-15 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F5, F5
• Sold 411,906 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-15 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6, F1, F7, F7
• Sold 471,483 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-15 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6, F1, F8, F8

Footnotes:

• F1: Pursuant to an agreement between the Reporting Person and the Issuer, effective as of April 15, 2026, the Issuer shall deliver to the Reporting Person Class A Ordinary Shares instead of Class B Ordinary Shares upon vesting of these Restricted Stock Units ("RSUs"). The vesting conditions for these RSUs remain unchanged.
• F2: Represents 1,006,250 Class A Ordinary Shares issuable upon the vesting of the same number of RSUs granted to the Reporting Person. The RSUs will vest subject to the satisfaction of certain service-based conditions.
• F3: Represents shares sold pursuant to a Rule 10b5-1(c) plan that was adopted by the Reporting Person on November 11, 2025.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $3.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price in those transactions.
• F5: Each Class B Ordinary Share is convertible into one Class A Ordinary Share at the option of the holder and has no expiration date.
• F6: Each RSU represents a contingent right to receive one Class B Ordinary Share.
• F7: The RSUs will vest equally on March 1, 2027 and March 1, 2028, subject to the satisfaction of certain service-based conditions.
• F8: The RSUs will vest equally on March 1, 2027, March 1, 2028 and March 1, 2029, subject to the satisfaction of certain service-based conditions.